Senate unveils its version of accelerated approval reforms as bipartisan duo calls on FDA and PTO to work together
The Senate is joining its House counterparts and advancing accelerated approval pathway reforms to the FDA user fee legislation that must be signed by President Joe Biden before the end of September or else the FDA will have to start laying off its staff.
While Sen. Richard Burr (R-NC) warned yesterday that the user fee deals could be delayed by the infant formula crisis, the newly introduced bill on Friday shows how the Senate is aligning with its House counterparts on similar accelerated approval reforms.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,600+ biopharma pros reading Endpoints daily — and it's free.